Your browser doesn't support javascript.
loading
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Dolinska, Monika; Cai, Huan; Månsson, Alma; Shen, Jingyi; Xiao, Pingnan; Bouderlique, Thibault; Li, Xidan; Leonard, Elory; Chang, Marcus; Gao, Yuchen; Medina, Juan Pablo; Kondo, Makoto; Sandhow, Lakshmi; Johansson, Anne-Sofie; Deneberg, Stefan; Söderlund, Stina; Jädersten, Martin; Ungerstedt, Johanna; Tobiasson, Magnus; Östman, Arne; Mustjoki, Satu; Stenke, Leif; Le Blanc, Katarina; Hellström-Lindberg, Eva; Lehmann, Sören; Ekblom, Marja; Olsson-Strömberg, Ulla; Sigvardsson, Mikael; Qian, Hong.
Afiliación
  • Dolinska M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Cai H; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Månsson A; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Shen J; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Xiao P; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Bouderlique T; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Li X; Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Leonard E; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Chang M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Gao Y; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Medina JP; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Kondo M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Sandhow L; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Johansson AS; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Deneberg S; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Söderlund S; Division of Hematology, Department of Medical Science, University Hospital, Uppsala, Sweden.
  • Jädersten M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Ungerstedt J; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Tobiasson M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Östman A; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Mustjoki S; Hematology Research Unit Helsinki, University of Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Stenke L; Translational Immunology Research Program, Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
  • Le Blanc K; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
  • Hellström-Lindberg E; Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Lehmann S; Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
  • Ekblom M; Division of Clinical Immunology & Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Olsson-Strömberg U; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Sigvardsson M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Qian H; Division of Hematology, Department of Medical Science, University Hospital, Uppsala, Sweden.
Blood ; 142(1): 73-89, 2023 07 06.
Article en En | MEDLINE | ID: mdl-37018663
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Médula Ósea / Leucemia Mielógena Crónica BCR-ABL Positiva Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Médula Ósea / Leucemia Mielógena Crónica BCR-ABL Positiva Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos